Peter H. Diamandis

Consider accumulating Robinhood Markets (HOOD) as it captures a massive long-term customer base through its exclusive U.S. Treasury child-savings partnership for 2025–2028 cohorts alongside the rollout of AI-driven agentic trading.

Retail investors seeking exposure to late-stage private tech leaders like OpenAI and Crusoe should consider buying Robinhood Ventures Fund 1, a liquid fund traded on the NASDAQ and NYSE that features a 0% carry fee structure.

Capitalize on the global expansion of tokenized real-world assets (RWA) via international platforms like Robinhood Chain, which facilitates 24/7 trading and instant settlement for tokenized shares of giants like SpaceX and NVIDIA.

Use recent price pullbacks to build positions in Bitcoin (BTC) following its run above $100,000, leveraging its durable retail adoption base and deepening integration into traditional financial products.

Position for rapid commercial growth in humanoid robotics by targeting real-world data collection and hardware providers ahead of expected unsupervised home and industrial deployments by the end of 2026.

Investors looking for near-term healthcare exposure to artificial intelligence should look to Novo Nordisk A/S (NVO), which is leveraging a new enterprise partnership with Anthropic to accelerate drug discovery timelines and cut research costs. Alphabet Inc. (GOOGL) remains a compelling mega-cap investment as it solidifies its enterprise cloud moat by heavily incentivizing developers to build autonomous businesses on Gemini. Watch for a potential public market entry from Anthropic, which represents a premier enterprise AI opportunity targeting a $2 trillion valuation supported by 80% gross margins and positive cash flow. Conversely, public equity investors should rule out an OpenAI listing in the near term, as leadership has officially postponed any IPO until after 2026 to navigate high cash burn and governance priorities.

Investors should target United Therapeutics Corporation (UTHR) for near-term upside, driven by commercial manufacturing facility openings for its Xenokidney and an advancing 50-patient Phase 3 XenoHeart clinical trial. UTHR also offers a high-conviction long-term pipeline with lab-grown autologous kidneys entering trials by 2028 and thymic rejuvenation therapies targeting commercial availability in the 2030s. In the broader regenerative medicine market, monitor rapid manufacturing breakthroughs in induced pluripotent stem cells (iPSCs) alongside organ transport logistics, such as eVTOL developer BETA Technologies. Near-term tech allocations should focus on artificial intelligence developers deploying custom LLMs and digital avatars that expand corporate productivity. Looking further out into the 2030s, investors should track emerging legal and financial infrastructure designed to monetize autonomous digital agents and digital personhood.

Diversify AI hardware exposure beyond NVIDIA (NVDA) by allocating to Advanced Micro Devices (AMD) and emerging photonic compute developers ahead of an expected industry shift over the next 18 to 24 months.

Invest in the physical bottlenecks of data center expansion by targeting natural gas pipeline operators alongside manufacturers of Coolant Distribution Units (CDUs) and Thermal Control Systems (TCSs).

Monitor preventive healthcare company Fountain Life for private equity and regional franchise licensing opportunities as it launches a global rollout over the next 6 to 9 months.

Monetize structured, proprietary engineering and medical data immediately through strategic acquisitions and data-licensing deals with buyers like Scale AI and Mercor.

Deploy venture capital into Brain-Computer Interfaces (BCIs) and autonomous construction robotics to capitalize on accelerating regulatory clearances and early commercial adoption over the next few years.

Investors should maintain exposure to NVIDIA (NVDA) as sustained compute shortages and a 22% monthly surge in H100 GPU rental rates turn AI hardware into durable, long-term cash-flow assets.

Conversely, monitor downside risk in specialized memory suppliers like SK Hynix, as emerging software optimizations increasingly bypass expensive High Bandwidth Memory (HBM).

Keep an eye out for upcoming public market liquidity in Anthropic, which is pacing toward a potential $2 trillion mega-IPO backed by an explosive $26 billion annualized revenue run rate and dominance in AI coding.

In biopharma, Moderna (MRNA) faces a critical 6-to-12-month window to integrate AI-driven development into its pipeline or risk margin compression against rapidly advancing AI-native biotech competitors.

Within enterprise finance, Envestnet (ENV) presents a compelling consolidation play as its integration of Vestmark creates a $10 trillion WealthTech powerhouse positioned to monetize proprietary data through automated AI infrastructure.

Investors should maintain exposure to NVIDIA (NVDA) for core AI infrastructure, as dominant high-end training demand for Blackwell and upcoming Vera Rubin chips secures its strong pricing power. Tesla (TSLA) offers a high-conviction autonomous mobility opportunity as it rolls out its capital-light CyberCab fleet platform at an accessible $30,000 price point to generate high-margin network revenue. Investors can also capitalize on physical bottlenecks in the $500 billion AI buildout by buying into "picks and shovels" themes, specifically industrial cooling, electrical equipment, and utility providers. Over the next 12 to 18 months, target enterprise software partnerships poised to benefit from collapsing AI inference costs that will accelerate corporate productivity. Finally, gain long-term exposure to humanoid robotics and industrial automation as essential macroeconomic hedges against shrinking global working-age populations.

Consider building a position in Tesla (TSLA) ahead of its planned rollout of 5,000 commercial Cybercabs in Nevada over the next 12 months, which aims to disrupt ride-sharing with an ultra-low $0.20-per-mile operating cost. Maintain core exposure to NVIDIA (NVDA) as demand for next-generation GB300 Blackwell chips and its $18 billion software acquisitions solidify its AI compute dominance. Accumulate leading GLP-1 drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY) to capture expanding multi-billion-dollar addressable markets as treatments broaden into longevity and preventative healthcare. Invest in natural gas infrastructure for a near-term 2-to-3-year transition play, while building long-term exposure to Small Modular Reactors (SMRs) ahead of their commercial AI data center buildout over the next 5 to 7 years. Add Salesforce (CRM) to gain exposure to enterprise software monetization through its strategic partnership with Anthropic to deploy cost-efficient autonomous AI agents.

Allocate capital toward Data Center Power and Physical Infrastructure—specifically electrical equipment manufacturers, cooling technologies, and Liquefied Natural Gas (LNG) providers—to profit from critical grid bottlenecks ahead of 2027.

Build long-term exposure to Tesla (TSLA) as its valuation increasingly benefits from high-margin grid-scale energy storage and a massive 100-gigawatt solar manufacturing expansion designed to power next-generation compute.

Invest in enterprise software leaders like Salesforce (CRM) and cloud platforms like Amazon (AMZN) as they shift to highly lucrative outcome-based AI pricing models over simple compute billing.

Consider managing risk on NVIDIA (NVDA) over a multi-year horizon, as emerging AI-driven chip design tools lower barriers for custom silicon and threaten hardware profit margins.

Track the Artificial General Intelligence (AGI) theme closely over the next four months, as frontier labs like OpenAI target major automated research benchmarks that will drive the next wave of deep tech disruption.

• Maintain core exposure to NVIDIA (NVDA) to capture massive near-term momentum following strong forward guidance of $108 billion for next quarter, while keeping a close eye on TSMC supply chain risks.
• Buy Broadcom (AVGO) to capitalize on the industry's shift toward custom AI silicon, highlighted by its breakthrough Jalapeno inference chip co-developed with OpenAI that significantly undercuts competitor power consumption.
• Accumulate Tesla (TSLA) to trade the near-term catalyst of deploying 2,500 CyberCabs in Las Vegas over the next year as the company works toward a high-margin, $100 billion robotaxi revenue target.
• Invest in Alibaba Group (BABA) to gain low-cost exposure to the commercial AI media boom, powered by its newly launched WAN 3.0 video generation model serving the 70% of Chinese compute demand driven by visual content.
• Establish long-term positions in Nuclear Energy and Small Modular Reactors (SMRs) to profit from the critical domestic HALEU fuel breakthroughs needed to power AI data centers ahead of target 2030 commercial grid rollouts.

Investors should maintain a bullish stance on NVIDIA (NVDA) as its $6 billion push into open-source AI software solidifies developer lock-in and secures sustained demand for its Blackwell chips. Alphabet (GOOGL) offers strong upside as Waymo slashes next-generation vehicle production costs down to $75,000, significantly accelerating its timeline toward profitable robotaxi commercialization. Reduce exposure to legacy satellite aviation providers like Viasat (VSAT), Gogo (GOGO), and Eutelsat (EUTLF), which face severe revenue disruption from the rapid adoption of SpaceX’s Starlink. Approach Intel (INTC) with caution, as its heavy $2 billion quarterly cash burn for Foundry expansion will continue to suppress profit margins in the short term. Finally, monitor proprietary enterprise software models for margin compression as ultra-low-cost Chinese Open-Weight AI alternatives rapidly commoditize general artificial intelligence workloads.

Investors should target Moderna (MRNA), Merck & Co. (MRK), and genetic testing partner Personalis (PSNL) to capitalize on breakthrough Phase 3 trial results validating personalized mRNA cancer vaccines.

Capitalize on critical hardware bottlenecks by establishing positions in High-Bandwidth Memory (HBM) producers like SK Hynix (000660.KS), which enjoy massive pricing power with data center production capacity already contracted through 2027.

Buy Uber Technologies (UBER) to capture future profit margin expansion as its logistics partnership with Zipline aims to scale to over one million autonomous drone deliveries per day to significantly reduce driver labor costs.

Prepare for an upcoming public market debut from leading artificial intelligence lab Anthropic, with prediction markets pricing the high-growth model developer near a $2 trillion valuation.

Track early-stage Custom AI Inference Hardware makers like Etched as a disruptive long-term theme designed to achieve massive efficiency gains over traditional computer chips.

Investors should reduce exposure to broad AI infrastructure and high-end hardware makers like NVIDIA (NVDA) over the next 2 to 3 years due to elevated valuations, excessive private debt, and emerging foreign chip competition.

Reallocate capital toward energy and power infrastructure, specifically targeting low-cost utility generation and electrical grid equipment that solve critical data center electricity bottlenecks.

Hold Taiwan Semiconductor Manufacturing Company (TSM) as an essential semiconductor manufacturing play, using its CHIPS Act-funded US factory expansion over the next 2 to 3 years as a hedge against geopolitical risk.

Capitalize on open-source software growth by investing in Alibaba Group Holding Limited (BABA), which is rapidly gaining global developer market share through its Qwen model ecosystem without incurring heavy hosting costs.

Prioritize investments in fixed industrial automation and domain-specific enterprise software applications over generic AI models and complex bipedal humanoid robotics, which face severe industry consolidation over the next 1 to 2 years.

Investors can capitalize on institutional AI Infrastructure expansion through alternative asset managers like Blackstone (BX), BlackRock (BLK), and KKR (KKR), which are partnering with NVIDIA (NVDA) to deploy over $500 billion into compute-backed debt vehicles through 2029.

In the Urban Air Mobility market, Joby Aviation (JOBY) and Archer Aviation (ACHR) present near-term commercialization plays as both advance through late-stage FAA certifications for passenger launches scheduled between 2024 and 2027.

Meta Platforms (META) offers high-conviction exposure to consumer edge artificial intelligence, leveraging its 3-billion-plus user ecosystem to capture market share through on-device models while actively mitigating physical data center expansion risks.

For long-term secular growth, position in the emerging Longevity Biotechnology theme by tracking next-generation peptide therapeutics such as Retatrutide and AI-driven computational biology platforms ahead of major clinical milestones targeted for 2030.

Treat compute as a tradable commodity by taking advantage of new futures markets on platforms like Kalshi, allowing you to hedge against AI infrastructure shortages or speculate on GPU pricing volatility.

Capitalize on ongoing high demand for advanced hardware by maintaining a bullish position in NVIDIA (NVDA), as strong pricing power for chips like the H100 and Blackwell series defies deflationary expectations.

Recognize that Google / Alphabet (GOOGL) is shifting its strategy from trailing the frontier AI model race to aggressively monetizing its cloud and TPU compute infrastructure.

Use these emerging compute derivative markets to protect your enterprise technology budgets against sudden price spikes over the coming year.

Capitalize on the recent 5% pullback in Alphabet (GOOGL) shares, as its massive cloud infrastructure and distribution footprint secure its role as a vital utility provider for the AI ecosystem. Consider taking a long position in Alibaba (BABA) following its 7% Hong Kong stock surge, driven by the release of its highly cost-effective Qwen 3.8 Max AI model priced 80% below Western competitors. Keep SpaceX on your radar as a future private-market cornerstone, targeting an ambitious $100 billion in annual recurring revenue by year-end and scaling toward massive semiconductor and orbital compute projects by 2027. Monitor the upcoming Nvidia (NVDA) partnership with SpaceX ahead of their 2027 orbital deployment of Rubin GPUs, which cements both companies as critical infrastructure plays for the AI sector.

Capitalize on government-backed AI infrastructure leaders like Nvidia and AMD, alongside supply chain partners such as Corning, to capture massive federal and commercial order volumes. Position yourself in the emerging quantum computing sector, focusing on firms developing molecular simulation technologies to disrupt the pharmaceuticals and drug discovery industry. Accumulate shares in cutting-edge diagnostics and preventative health technologies that offer early-stage cancer screening and full-body MRIs. Target innovative biotechnology companies focused on extending human health span rather than traditional reactive healthcare models. Monitor government-backed sectors like commercial fusion energy and domestic robotics manufacturers to capitalize on strong regulatory tailwinds.

Accumulate shares of Alphabet Inc. (GOOGL) to capitalize on its aggressive enterprise push into real-world AI applications through the Gemini ecosystem. Monitor Alphabet's (GOOGL) ongoing Google X moonshot projects as a long-term indicator for breakthrough industry-shifting technologies. Although Colossal Biosciences is private, investors should use its de-extinction milestones as a signal to buy into the broader, high-growth synthetic biology and genetic engineering sectors. Keep a close watch on private defense tech leader Anduril Industries for surging commercial demand in autonomous hardware, which reflects strong tailwinds for publicly traded defense contractors.

Buy NVIDIA (NVDA) to capitalize on the booming infrastructure layer, as the company profits from massive GPU demand regardless of whether the market adopts open-source or proprietary AI models. Monitor the upcoming August 1st deadline for federal AI regulations, as lobbying efforts by major players like Anthropic and OpenAI could establish regulatory moats that squeeze smaller competitors. Look for long-term growth opportunities in Meta (META), which is uniquely positioned to dominate the application layer by monetizing AI models directly through its massive consumer ecosystems like WhatsApp and Instagram.

Investors seeking exposure to the growing commercial space economy should monitor Rocket Lab (RKLB) as a prime publicly traded option in reusable rocketry. Closely track the development and deployment timeline of the Neutron vehicle as a major growth catalyst for the company's small-to-medium launch market share. Keep an eye out for any future public announcements regarding a potential SpaceX IPO to secure a direct stake in dominant orbital infrastructure and space data centers. Watch competitors like Blue Origin and their New Glenn vehicle as heavy-lift launch capacities continue to drive down mass-to-orbit costs. Capitalize on these themes by positioning for long-term growth in the emerging lunar economy and government contracting space over the next several years leading up to the 2028 lunar missions.